Andractim (Topical Dihydrotestosterone)

Andractim DHT, despite being more potent than testosterone in terms of anabolic and androgenic effects, carries several potential side effects and challenges with its topical administration. However, it also offers some advantages due to its formulation.

First, let’s briefly discuss Andractim DHT.

Pure Andractim DHT isn’t the best choice for promoting anabolism. Despite its high anabolic/androgenic rating, the body’s metabolism of DHT often doesn’t yield desired results. However, let’s start with the positives.

Andractim DHT is a non-aromatizing androgen, meaning it doesn’t convert to estrogen. This is significant because estrogen can suppress LH production, leading to a decrease in endogenous testosterone levels. Unlike testosterone, Andractim DHT doesn’t inhibit LH or testosterone production and may even suppress estrogen in some cases. This property may explain its ability to positively influence LH and testosterone levels.

But there’s a downside. Much of the DHT is metabolized into inactive compounds before reaching skeletal muscle androgen receptors. While effective for the scalp and prostate, its efficacy in muscle tissues is limited. This explains the diverse range of DHT alterations available in the market, each with specific uses. Among them, Andractim serves a unique purpose.

Andractim has shown some success in reducing gynecomastia in males. Since decreased circulating DHT levels can cause gynecomastia, androgen therapy with DHT derivatives has proven effective in its treatment. Hence, the use of topical DHT seems logical for managing gynecomastia induced by anabolic/androgenic steroid use. However, its application method poses a challenge:

You need to apply it directly to the nipples several times a day.

Clearly, this regimen presents practical issues, especially for individuals with work commitments who cannot conveniently access restroom facilities for nipple application throughout the day—unless, of course, nipple rubbing is a job requirement.

Andractim uses and drawbacks

Andractim, also known as dihydrotestosterone (DHT) gel, primarily treats low testosterone levels in men, a condition known as hypogonadism. DHT, a potent androgen, promotes the development and maintenance of male characteristics.

Uses:

• Hypogonadism: Andractim supplements testosterone levels in men with deficient or low testosterone production, alleviating symptoms such as decreased libido, erectile dysfunction, fatigue, and decreased muscle mass.
• Micropenis: Andractim may be prescribed to promote penile growth in cases of micropenis, where the penis is abnormally small.
• Gender-affirming therapy: While less common than other forms of testosterone supplementation, Andractim is used in masculinizing hormone therapy for transgender men due to its potency, though its availability is limited in some regions.

Drawbacks:

• Skin irritation: Andractim, applied topically, can cause irritation at the application site, manifesting as redness, itching, or a rash, potentially leading to intolerable discomfort or allergic reactions.
• Potential for transfer: Skin contact with Andractim gel poses a risk of transferring androgens to others, especially women and children, resulting in unintended exposure and virilization in women and adverse effects in children.
• Limited availability: In certain regions, Andractim may not be readily accessible or approved for use, limiting its availability to patients who could benefit from it.
• Cost: Andractim can be costly, particularly if not covered by insurance, posing a barrier to access for some individuals depending on healthcare coverage and location.
• Regulatory concerns: The use of DHT gel in transgender hormone therapy raises controversy due to its potency, potential side effects, and regulatory restrictions in some countries.
• Effects on cholesterol levels: Like other testosterone replacement therapies, Andractim may impact cholesterol levels, potentially increasing LDL cholesterol (the “bad” cholesterol) while decreasing HDL cholesterol (the “good” cholesterol), thereby increasing the risk of cardiovascular disease in some individuals.

Bibliography

1. Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-reductase inhibitor ONO-3805. J Androl. 1994 Nov-Dec;15(6):521-7.
2. Male pseudohermaphroditism due to 5 alpha reductase deficiency associated with gynecomastia. Rev Hosp Clin Fac Med Sao Paulo. 1987 Mar-Apr;42(2):66-8.
3. Crystalline dihydrotestosterone implants in the lateral septum of male rats. A positive effect on LH and FSH. Endocr Res. 2001 Feb-May;27(1-2):35-40.
4. Inhibition of LH Secretion by Localized Administration of Estrogen, but not Dihydrotestosterone, Is Enhanced in the Ventromedial Hypothalamus During Feed Restriction in the Young Wether. Biol Reprod. 2005 Jun 22; [Epub ahead of print]
5. Case report: finasteride-induced gynecomastia in a 62-year-old man. Am J Med Sci. 1995 Jun;309(6):322-5.
6. Hypothalamic sites of action for testosterone, dihydrotestosterone, and estrogen in the regulation of luteinizing hormone secretion in male sheep. Endocrinology. 1997 Sep;138(9):3686-94.